Spondyloarthritis & psoriatic arthritis
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial
Authors' conclusion
Participants with active PsA and complex inflammatory-metabolic disease achieved clinically meaningful improvement of PsA, physical function, weight reduction, and quality of life when treated with IXE + TZP compared to IXE alone, with no new safety concerns.
Study context
- Population
- Adults with active psoriatic arthritis (PsA) and overweight (BMI ≥27 to <30) with at least one weight-related comorbidity or obesity (BMI ≥30)randomised
- Participants
- 271 adults
- Comparison
- Ixekizumab (IXE) + tirzepatide (TZP) vs IXE alone
- IXE + TZPn = 138
- IXEn = 133reference
- Primary endpoint
- Simultaneous achievement of ACR50 and ≥10% weight reduction
- Follow-up
- 36 weeks
Methodological detailsphase 3b, 52-week
- Phase 3b
- 52-week
Primary result
As reported in the abstract
ACR50 and ≥10% weight reduction
P < 0.001
Secondary outcomes
ACR50 (key secondary) · significant early separation at week 4 (nominal P < 0.05)
P = 0.02
| Outcome | Estimate | P value |
|---|---|---|
| HAQ-DI | ∆ −0.2 | nominal P < 0.001 |
| FACIT-Fatigue | improvement 3.8 | nominal P < 0.01 |
- ACR20 · nominally significant improvement
- P < 0.001
- MDA · nominally significant improvement
- P < 0.05
- Absolute PASI score · nominally significant improvement
- P < 0.01
Safety
Safety (adverse events (AEs), TEAEs, serious AEs)
- Safety profiles consistent with previous studies for each drug
Original publication
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. Published 28 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →